|
|
|
|
31st July, 2008
Second Quarter and Half Year Results 2008
AstraZeneca PLC Second Quarter and Half Year Results 2008 Download the narrative and the figures.
|
23rd July, 2008
AstraZeneca and Bristol-Myers Squibb Submit New Drug Application in the United States and Marketing Authorisation Application in Europe for ONGLYZA™ (Saxagliptin) for the Treatment of Type 2 Diabetes
AstraZeneca and Bristol-Myers Squibb Company today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) on June 30th and validation of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for ONGLYZA™ (saxagliptin) ...
|
2nd July, 2008
Summary Judgment Granted for SEROQUEL Patent Litigation in the US
AstraZeneca today announced that the US District Court for the District of New Jersey has granted the company's Motion for Summary Judgment of No Inequitable Conduct. AstraZeneca had sued Teva Pharmaceutical Industries Ltd ...
|
26th June, 2008
AstraZeneca Announces Senior Management Changes at Biologics Business Unit, MedImmune
AstraZeneca today announced that Dave Mott, President and Chief Executive Officer (CEO) of its biologics business unit, MedImmune, has decided to leave the company at the end of July. Tony Zook, CEO of AstraZeneca’s North American business and Executive Vice President of Global Marketing, has been appointed as head of MedImmune on an interim basis until a permanent successor is identified.David Brennan, CEO of AstraZeneca, said: “Under Dave Mott’s leadership, the team at MedImmune has built a unique capability to discover, develop and deliver innovative biologic treatments – an important element of AstraZeneca’s future strategy ...
|
17th June, 2008
AstraZeneca and Columbia University Medical Center Sign Strategic Research Collaboration to Develop Novel Therapeutics for Diabetes and Obesity
AstraZeneca and Columbia University Medical Center in New York today announced that they have entered into a strategic research collaboration in metabolic related diseases, to develop novel therapeutics primarily in type 2 diabetes and obesity and, with a secondary focus on atherosclerosis (hardening of the arteries)/dyslipidaemia (abnormal blood lipid levels).The preclinical and clinical research will focus on discovering mechanisms and identifying new biological targets for intervention that have the potential of being starting points for successful and commercially viable treatments to tackle these diseases that are major risk factors for cardiovascular morbidity and mortality.Obesity and type 2 diabetes are now widely regarded as the largest and most rapidly growing health problems ...
|
10th June, 2008
AstraZeneca Submits Seroquel XR™ in Europe for the Treatment of Major Depressive Disorder
AstraZeneca today announced that the company has submitted applications in the European Union (EU) for once-daily SEROQUEL XR™ (quetiapine fumarate) Extended-Release Tablets (quetiapine XR), seeking approval for the treatment of major depressive disorder (MDD) including maintenance therapy in adult patients using the Mutual Recognition Procedure (MRP) ...
|
4th June, 2008
AstraZeneca Submits an sNDA for SYMBICORT® for the Treatment of Asthma in Children as Young as Age Six
AstraZeneca today announced that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for approval of a new indication for SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol for the long-term maintenance treatment of asthma in paediatric patients ages 6 to 11 years old ...
|
14th May, 2008
FDA Approves AstraZeneca’s Seroquel for Maintenance Treatment in Bipolar Disorder
AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved SEROQUEL® (quetiapine fumarate) for the maintenance treatment of patients with bipolar I disorder, as adjunct to lithium or divalproex ...
|
8th May, 2008
AstraZeneca Submits sNDA for Seroquel XR™ for the Treatment of Generalised Anxiety Disorder — a First for the Atypical Antipsychotic Class of Medicines
AstraZeneca today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for SEROQUEL XR™ (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of generalised anxiety disorder (GAD), including maintenance of antianxiety effect ...
|
6th May, 2008
EPO Announces Symbicort® European COPD Use Patent Decision
AstraZeneca today announced that the European Patent Office (EPO) Technical Board of Appeal has made a final ruling that the European Combination patent covering the use of Symbicort® (formoterol and budesonide) for the treatment of chronic obstructive pulmonary disease (COPD) (EPB1014993) has been revoked, following an appeal from generic manufacturers Norton Healthcare and Generics UK ...
|
|
|
|
« Previous 10 Next 10 » |
